FilingSEC EDGAR8-K
Rein Therapeutics Releases LTI-03 Clinical Data and Development Update
· SEC accepted
StagePhase 2
Filing content
The company released investor presentation materials detailing Phase 1b clinical results for its IPF candidate LTI-03 and the ongoing RENEW Phase 2 trial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…